Bernhard Kirschbaum and Oliver Schacht

Protagen has appointed Bernhard Kirschbaum as chairman of its supervisory board and Oliver Schacht as a new board member. Kirschbaum is a former Merck executive and has been a member of the Protagen board since 2015. He is taking over as the role of chairman from Axel Kleemann, who has served in the position for the past 15 years. Schacht successfully completed the IPO of Curetis last November, and has served in executive positions at Epigenomics in Seattle and in Berlin. He is currently a member of the executive board of BioDeutchland.